On March 18, 2019, the FDA granted accelerated approval for atezolizumab plus nab-paclitaxel to treat patients with unresectable, locally advanced or metastatic TNBC, whose tumor immune cells express PD-L1 at 1% or higher using the Ventana SP142 assay (72). The gene discussed is CD274; the disease is neoplasm.